Trial Profile
A Randomized, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Adomiparin (Primary) ; Heparin
- Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMINENCE
- Sponsors Momenta Pharmaceuticals
- 07 Apr 2010 Results were published in Circulation, according to a Momenta Pharmaceuticals media release.
- 02 Oct 2009 Actual patient number (503) added as reported by ClinicalTrials.gov.
- 02 Oct 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.